外周血生物标志物与非小细胞肺癌纳武利尤单抗治疗结局相关
该回顾性研究纳入134例接受纳武利尤单抗治疗的晚期或复发非小细胞肺癌患者,分析治疗前外周血参数与生存的关系。多因素分析显示低中性粒细胞绝对计数、高淋巴细胞绝对计数和高嗜酸性粒细胞绝对计数独立关联更好的无进展生存和总生存。根据有利因素数量分组可区分不同生存和缓解率的患者亚组。
要点
- 基线低ANC、高ALC、高AEC独立关联更优PFS和OS。
- 有利因素数量(1个 vs 2-3个)可区分生存和缓解率亚组。
- PD-L1 TPS≥50%患者均至少有2个有利因素。
核心结论
- 基线低ANC、高ALC、高AEC的特征与纳武利尤单抗治疗更好结局相关。
- 有利因素数量可识别生存和缓解率不同的患者亚组。
研究设计与样本
- 回顾性研究纳入134例接受纳武利尤单抗治疗的晚期或复发NSCLC患者。
- 分析治疗前外周血参数与生存的关系,采用单因素和多因素分析。
主要发现
- 多因素分析中,低ANC与更好PFS显著独立关联(p=0.001),与更好OS关联(p=0.03)。
- 高ALC与更好PFS显著独立关联(p=0.04),与更好OS关联(p=0.03)。
- 高AEC与更好PFS显著独立关联(p=0.02),与更好OS关联(p=0.003)。
- 仅1个有利因素的患者结局显著差于2或3个有利因素的患者。
- PD-L1 TPS<50%患者中类似趋势明显,而TPS≥50%患者均至少有2个有利因素。
临床怎么用
- 治疗前可检测ANC、ALC、AEC等外周血参数辅助评估纳武利尤单抗治疗预后。
- 根据有利因素数量对患者进行分层,可能有助于识别不同生存和缓解率亚组。
局限性
- 回顾性研究设计。
- 样本量有限(134例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to identify baseline peripheral blood biomarkers associated with clinical outcome in patients with NSCLC treated with nivolumab. METHODS: Univariable and multivariable analyses were performed retrospectively for 134 patients with advanced or recurrent NSCLC treated with nivolumab to evaluate the relationship between survival and peripheral blood parameters measured before treatment initiation, including absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count, and absolute eosinophil count (AEC), as well as serum C-reactive protein and lactate dehydrogenase levels. Progression-free survival, overall survival, and response rate were determined. RESULTS: Among the variables selected by univariable analysis, a low ANC, high ALC, and high AEC were significantly and independently associated with both better progression-free survival (p = 0.001, p = 0.04, and p = 0.02, respectively) and better overall survival (p = 0.03, p = 0.03, and p = 0.003, respectively) in multivariable analysis. Categorization of patients according to the number of favorable factors revealed that those with only one factor had a significantly worse outcome than those with two or three factors. A similar trend was apparent for patients with a programmed death 1 ligand tumor proportion score less than 50%, whereas all patients with a score of 50% or higher had at least two favorable factors. CONCLUSIONS: A baseline signature of a low ANC, high ALC, and high AEC was associated with a better outcome of nivolumab treatment, with the number of favorable factors identifying subgroups of patients differing in survival and response rate.
引用
- Tanizaki J, Haratani K, Hayashi H, et al. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. J Thorac Oncol. 2017. PMID: 29170120. doi:10.1016/j.jtho.2017.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。